Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Heparin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    435 result(s) found for: Heparin. Displaying page 8 of 22.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2018-000230-35 Sponsor Protocol Number: 014-FPO18 Start Date*: 2018-10-17
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced ...
    Medical condition: platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005075-40 Sponsor Protocol Number: 2013-005075-40 Start Date*: 2014-04-08
    Sponsor Name:Research Programs' Unit, Diabetes & Obesity, University of Helsinki
    Full Title: The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study.
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004692-40 Sponsor Protocol Number: PPL20 Start Date*: 2021-03-30
    Sponsor Name:Dilafor AB
    Full Title: An Exploratory, Open label, Randomized, Parallel-Group, Pilot Study to evaluate Safety, Tolerability and Efficacy of daily, subcutaneous tafoxiparin treatment from the time of diagnosis for up to 4...
    Medical condition: Preeclampsia diagnosed at week 26-32 of gestation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10040444 Severe pre-eclampsia LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000181-34 Sponsor Protocol Number: OBI-1-301 Start Date*: 2011-06-29
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
    Medical condition: Acquired Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10053761 Acquired hemophilia with anti FVIII, XI, or XIII LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004412-38 Sponsor Protocol Number: 1160.248 Start Date*: 2017-01-09
    Sponsor Name:Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
    Full Title: RE-SPECT CVT: a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients wit...
    Medical condition: cerebral vein and dural sinus thrombosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10008209 Cerebrovascular venous and sinus thrombosis HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) NL (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013618-29 Sponsor Protocol Number: 1160.89 Start Date*: 2010-08-17
    Sponsor Name:Boehringer Ingelheim France
    Full Title: Open-label safety and tolerability of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 years...
    Medical condition: Venous Thrombotic Event
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066899 Venous thromboembolism LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) ES (Completed) LT (Prematurely Ended) SK (Completed) LV (Prematurely Ended) IT (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004620-40 Sponsor Protocol Number: BAY 59-7939/11356 Start Date*: 2006-01-26
    Sponsor Name:Bayer HealthCare AS
    Full Title: RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elec...
    Medical condition: Prevention of venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) DE (Completed) DK (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001341-14 Sponsor Protocol Number: BAY 59-7939 / 11527 Start Date*: 2004-11-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Controlled, Double-Blind, Randomized, Dose-ranging Study of once-daily regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement-ODIXaHIP-OD Study
    Medical condition: Deep Venous Thrombosis prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10012108
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) AT (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004378-10 Sponsor Protocol Number: EORTC 62043 Start Date*: 2005-08-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Multi-center, open-label, non-randomised phase II study to evaluate the activity and tolerability of GW786034 in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed follo...
    Medical condition: Advanced and/or metastatic Soft Tissue Sarcoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004495-13 Sponsor Protocol Number: BAY 59-7939/11702 Start Date*: 2007-03-12
    Sponsor Name:Bayer Healthcare AG
    Full Title: Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.
    Medical condition: Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) SE (Completed) FR (Completed) DE (Completed) FI (Completed) DK (Completed) HU (Completed) AT (Completed) IT (Completed) GB (Completed) CZ (Completed) NL (Completed) IE (Completed) LT (Completed) EE (Completed) LV (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003866-96 Sponsor Protocol Number: BEMI-2015 Start Date*: 2016-04-29
    Sponsor Name:ANGELA PUENTE
    Full Title: Randomized controlled trial on the safety and efficacy of low molecular weight heparins in the prevention of thrombotic events in hospitalized cirrhotic patients
    Medical condition: Prevention of thrombosis in cirrhotic patients
    Disease: Version SOC Term Classification Code Term Level
    18.1 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006866-27 Sponsor Protocol Number: 1160.88 Start Date*: 2012-03-15
    Sponsor Name:Boehringer Ingelheim (Canada) Ltd./Ltée
    Full Title: Open-label safety and tolerability study of dabigatran etexilate given for 3 days at the end of standard anticoagulant therapy in children aged 12 years to less than 18 years
    Medical condition: Venous Thrombotic Event
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10066899 Venous thromboembolism LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002914-10 Sponsor Protocol Number: 66856 Start Date*: 2019-09-16
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial
    Medical condition: Advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004373-23 Sponsor Protocol Number: ROV-BEM-2003-02 Start Date*: 2007-08-14
    Sponsor Name:LABORATORIOS FARMACEUTICOS ROVI, S.A.
    Full Title: MULTICENTRIC, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND THE SAFETY OF THE PROPHYLAXIS WITH BEMIPARIN 3,500 IU/day FOR 28 DAYS COMPARED TO 8 DAYS, IN V...
    Medical condition: VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS UNDERGOING ONCOLOGICAL ABDOMINAL OR PELVIC SURGERY
    Disease: Version SOC Term Classification Code Term Level
    6.1 10043640 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001090-15 Sponsor Protocol Number: MADONNA Start Date*: 2008-09-10
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.
    Medical condition: metastatic HER2-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002433-37 Sponsor Protocol Number: TUD-LENAMA-022 Start Date*: 2008-02-15
    Sponsor Name:Technische Universität Dresden
    Full Title: Lenalidomide maintenance therapy in patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation (HSCT)
    Medical condition: patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002888-24 Sponsor Protocol Number: CP-AF-1 Start Date*: 2005-03-15
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent non...
    Medical condition: Atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    M15 10003658 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002081-20 Sponsor Protocol Number: 2010_52 Start Date*: 2013-05-13
    Sponsor Name:CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE
    Full Title: A Multicenter Open label Phase II study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma patients with deletion 17p or translocation (4;14) Adverse Karyotypi...
    Medical condition: This study will determine the efficacy and toxicity profile of pomalidomide and dexamethasone in patients with adverse prognostic factors as determined using adverse karyotypic abnormalities and th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005529-22 Sponsor Protocol Number: H-6-2013-011 Start Date*: 2014-03-21
    Sponsor Name:Rigshospitalet
    Full Title: Platelet inhibition in comatose patients receiving oral anti platelet therapy through a naso-gastric tube after undergoing acute percutaneous coronary intervention
    Medical condition: Patients surviving cardiac arrest and undergoing percutaneous coronary intervention
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10067273 Acute transmural myocardial infarction LLT
    16.1 100000004849 10064347 Non ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001956-52 Sponsor Protocol Number: 001 Start Date*: 2014-08-07
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: Activity and safety of third line tyrosin kinase inhibitor (TKI) after 2 tyrosin kinase inhibitors(TKIs) in patients with metastatic renal cell carcinoma (mRCC) (Tokio Study)
    Medical condition: Metastatic renal cells carcinoma
    Disease: Version SOC Term Classification Code Term Level
    11.0 100000004864 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 00:08:13 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA